1 Eldadah ZA, Najjar SS, Ziegelstein RC. A patient with syncope, only "vagally" related to the heart.
Significant Omission in Antithrombotic Supplement
To the Editor:
In reviews of the treatment of venous thromboembolism, Hyers and colleagues [1] [2] [3] and the researchers in the 263 articles that they referenced neglected to mention a randomized trial by Nielsen et al, 4,5 comparing heparin and a phenprocoumon anticoagulation therapy with phenylbutazone therapy in patients with deep venous thrombosis (DVT). This is the only published randomized controlled trial comparing the treatment of DVT patients using standard anticoagulation therapy with control subjects who had not received anticoagulation therapy. It was a negative study with 1 of 48 anticoagulated patient dying of pulmonary emboli (PEs) and 0 of 42 patients receiving phenylbutazone therapy experiencing fatal PEs.
In the 1995 review, Hyers et al 1 state, "Patients with DVT or PE should be treated with IV heparin or adjusted-dose subcutaneous heparin sufficient to prolong the activated partial thromboplastin time to a range that corresponds to a plasma heparin level of 0.2 to 0.4 U/mL. This grade A recommendation is based on level I studies in patients with PE 6 and DVT. [7] [8] [9] The placebo-controlled randomized trial by Barritt and Jordan 6 of patients with PE is too old, small (n ϭ 35), and flawed to be considered as proof of the efficacy of anticoagulant therapy. 10 Barritt and Jordan 6 made the diagnosis based on clinical suspicion. We now know that only about 27% of patients suspected of having PEs actually have the diagnosis confirmed by angiogram or lung scan. 11 Of the five deaths in the control group, cases 1 and 4 had chronic septic cavitation of the lungs, with no recent embolization. The patient in case 2 had thrombophlebitis and thrombosis of the hepatic veins but no documented autopsy evidence of PE. In the patient in case 5, the cause of death was cerebral infarction. Consequently, only case 3 would meet a modern definition of fatal PE: "massive fresh emboli present in the main pulmonary artery, or in at least two lobar arteries, demonstrated post mortem in patients in whom no other cause of death was found." 12 None of the other randomized trials cited in the later reviews concerning DVT or PE had control subjects who were not anticoagulated. 7-9,13-16 Therefore, they do not provide "level 1" evidence of the efficacy of anticoagulant therapy in patients with PEs or DVT.
Heparin and vitamin K antagonists became the standard treatment for DVT and PE patients in the 1940s before the
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